GALK1

Across TCGA pan-cancer cohorts, GALK1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GALK1 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher GALK1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GALK1 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

SARC, LIHC, and UCEC are the cancer types where GALK1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.016	0.861	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.155	0.617	.009	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.172	0.693	.044	3	view →
BLCA	DFS	Median	III,IV	0.511	0.315	.047	2	view →
SKCM	OS	Median	II,III,IV	1.000	0.726	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GALK1–SARC (OS)

Open the SARC breakdown →